See more : EPH European Property Holdings Limited (EPH.SW) Income Statement Analysis – Financial Results
Complete financial analysis of SELLAS Life Sciences Group, Inc. (SLS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SELLAS Life Sciences Group, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Shouhang High-Tech Energy Co., Ltd. (002665.SZ) Income Statement Analysis – Financial Results
- HelloFresh SE (HLFFF) Income Statement Analysis – Financial Results
- eREX Co.,Ltd. (ERXCF) Income Statement Analysis – Financial Results
- Beazer Homes USA, Inc. (0HMG.L) Income Statement Analysis – Financial Results
- Microwave Filter Company, Inc. (MFCO) Income Statement Analysis – Financial Results
SELLAS Life Sciences Group, Inc. (SLS)
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 1.00M | 7.60M | 1.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.32M | 2.49M | 2.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 100.00K | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K | 355.00K | 1.40M | 520.00K | 0.00 | 20.79M | 0.00 | 0.00 | 0.00 | 11.41M | 0.00 |
| Gross Profit | 0.00 | 900.00K | 7.40M | 1.90M | 0.00 | 0.00 | 0.00 | -3.00K | -355.00K | 7.92M | 1.97M | 2.04M | -20.79M | 0.00 | 0.00 | 0.00 | -11.41M | 0.00 |
| Gross Profit Ratio | 0.00% | 90.00% | 97.37% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 84.94% | 79.09% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 24.01M | 30.27M | 21.37M | 9.28M | 7.29M | 18.32M | 6.07M | 19.86M | 23.61M | 28.35M | 21.08M | 14.61M | 11.54M | 7.87M | 8.89M | 7.05M | 6.75M | 1.30M |
| General & Administrative | 13.86M | 12.58M | 11.32M | 9.60M | 9.92M | 12.77M | 15.09M | 12.01M | 10.61M | 31.34M | 14.60M | 6.59M | 6.86M | 8.75M | 8.63M | 4.87M | 3.74M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.39M | 0.00 | 0.00 | 2.63M | 931.00K | 0.00 |
| SG&A | 13.86M | 12.58M | 11.32M | 9.60M | 9.92M | 12.77M | 15.09M | 12.01M | 10.61M | 31.34M | 14.60M | 6.59M | 9.25M | 8.75M | 8.63M | 7.50M | 4.67M | 633.00K |
| Other Expenses | 0.00 | 10.00M | 5.70M | 0.00 | 0.00 | -3.03M | 0.00 | 0.00 | 509.00K | 170.00K | 37.00K | -13.18M | 9.25M | 0.00 | 0.00 | 7.50M | 0.00 | 0.00 |
| Operating Expenses | 37.87M | 42.85M | 32.69M | 18.88M | 17.21M | 31.09M | 21.16M | 31.87M | 34.22M | 60.14M | 35.81M | 21.20M | 20.79M | 16.63M | 17.52M | 14.55M | 11.41M | 2.41M |
| Cost & Expenses | 37.87M | 42.95M | 32.89M | 18.88M | 17.21M | 31.09M | 21.16M | 31.87M | 34.22M | 61.54M | 36.33M | 21.20M | 20.79M | 16.63M | 17.52M | 14.55M | 11.41M | 2.41M |
| Interest Income | 525.00K | 317.00K | 6.00K | 26.00K | 118.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 180.00K | 448.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 118.00K | 266.00K | 462.00K | 3.51M | 760.00K | 1.11M | 807.00K | 33.00K | 0.00 | 5.00K | -5.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 37.87M | 457.00K | 1.27M | 377.00K | 17.21M | 22.04M | 3.00K | 3.00K | 355.00K | 440.00K | 452.00K | 49.00K | 163.00K | 172.00K | 162.00K | 131.00K | 36.00K | 0.00 |
| EBITDA | 529.00K | -31.95M | -19.66M | -16.40M | 668.00K | 0.00 | -23.04M | -15.99M | -37.48M | -36.61M | 7.63M | -34.38M | -11.32M | -11.82M | -18.22M | -14.24M | -10.93M | -2.41M |
| EBITDA Ratio | 0.00% | -4,228.20% | -390.08% | -888.53% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -733.32% | 306.71% | -1,040.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -37.87M | -41.95M | -25.29M | -16.98M | -20.04M | -31.09M | -23.04M | -31.87M | -34.22M | -52.22M | -33.84M | -21.20M | -20.79M | -16.63M | -17.52M | -14.55M | -11.41M | -2.41M |
| Operating Income Ratio | 0.00% | -4,195.00% | -332.82% | -893.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -560.38% | -1,360.68% | -1,040.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 529.00K | 649.00K | 4.36M | 208.00K | 668.00K | 2.54M | -7.79M | 5.13M | -4.37M | 13.62M | -41.79M | -13.18M | 9.30M | 4.63M | -867.00K | 180.00K | 448.00K | 0.00 |
| Income Before Tax | -37.34M | -41.30M | -20.94M | -16.77M | -19.37M | -29.05M | -23.50M | -10.86M | -38.59M | -36.61M | -75.63M | -34.38M | -11.49M | -11.99M | -18.39M | -14.37M | -10.97M | -2.41M |
| Income Before Tax Ratio | 0.00% | -4,130.10% | -275.47% | -882.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -392.81% | -3,040.85% | -1,686.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -649.00K | -237.00K | -17.00K | -81.00K | -1.38M | 253.00K | 243.00K | 365.00K | -15.45M | 1.05M | -1.05M | -9.30M | -4.63M | 867.00K | 0.00 | 25.00K | 0.00 |
| Net Income | -37.34M | -40.65M | -20.70M | -16.76M | -19.29M | -27.67M | -23.75M | -23.55M | -63.90M | -36.61M | -76.68M | -34.97M | -11.49M | -11.99M | -18.39M | -14.37M | -10.99M | -2.41M |
| Net Income Ratio | 0.00% | -4,065.20% | -272.36% | -881.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -392.81% | -3,083.15% | -1,715.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.34 | -2.10 | -1.34 | -2.10 | -7.54 | -105.80 | -507.49 | -3.55K | -12.35K | -9.20K | -25.51K | -16.80K | -9.48K | -19.60K | -34.05K | -31.38K | -26.04K | -5.73K |
| EPS Diluted | -1.34 | -2.10 | -1.34 | -2.10 | -7.54 | -105.80 | -507.49 | -3.55K | -12.35K | -9.20K | -25.51K | -16.80K | -9.48K | -19.60K | -34.05K | -31.38K | -26.04K | -5.73K |
| Weighted Avg Shares Out | 27.78M | 19.40M | 15.48M | 7.98M | 2.56M | 261.54K | 46.81K | 6.64K | 5.17K | 3.98K | 3.01K | 2.08K | 1.21K | 612.00 | 540.00 | 458.00 | 422.00 | 420.00 |
| Weighted Avg Shares Out (Dil) | 27.78M | 19.40M | 15.48M | 7.98M | 2.56M | 261.54K | 46.81K | 6.64K | 5.18K | 3.98K | 3.01K | 2.08K | 1.21K | 612.00 | 540.00 | 458.00 | 422.00 | 420.00 |
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
- Preselection Method for Cancers Responding to SLS009: High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers vs 0% in Non-ASXL1 Mutated Cancers –
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
– Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 –
voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)
FRIEDBERG, Germany--(BUSINESS WIRE)--voxeljet AG (OTCMKTS: VJTTY) (the ‘Company', ‘voxeljet', or ‘we'), a provider of high-speed, large-format 3D printers and on-demand parts services to industrial and commercial customers, Dressler Group GmbH, and Fraunhofer IPA today announced the successful completion of a...
SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024
- Presentation at ASH will Feature Results from the Phase 2a Trial of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia After Venetoclax Failure –
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia
- GPS Currently Investigated in Phase 3 REGAL Trial in Adult AML Patients – Interim Analysis Anticipated in Q4 2024 - - RPDD Provides Eligibility for GPS to Receive a Priority Review Voucher (PRV) Upon Marketing Approval that can be...
SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
NEW YORK, Oct. 10, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...
Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD
-Dosing of the SLS-002 cohort is expected to commence in 4Q2024 NEW YORK , Sept. 24, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders...
Galena Biopharma (SLS) Upgraded to Buy: Here's Why
Galena Biopharma (SLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Announced Independent Data Monitoring Committee's (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: Interim Analysis Anticipated by Q4 2024 -
SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...
Source: https://incomestatements.info
Category: Stock Reports